alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
The District Court of the 4th Judicial District. County of Missoula.

#### STATE OF MONTANA, Plaintiff, vs. MELISSA UMHEY, Defendant.

CAUSE NO. DC-08-437 DECISION

On December 7, 2009, the defendant was sentenced for violation of the conditions of a suspended sentence for the following offenses: Count II: A commitment to the Department of Corrections for a period of twenty (20) years, with fifteen (15) years suspended, for the offense of Forgery, a felony; and Count III: A commitment to the Department of Corrections for a term of twenty (20) years, with all time suspended, for the offense of Forgery, a felony. Counts II and III shall run concurrently. The Court recommends the defendant receive a psychological evaluation and enter any proper program to deal with her issues, such as the Elkhom program or other inpatient treatment program.

On April 2, 2010, the defendant’s application for review of that sentence was heard by the Sentence Review Division of the Montana Supreme Court.

The defendant was present and was represented by Kris Copenhaver. The state was not represented.

Before hearing the application, the defendant was advised that the Sentence Review Division has the authority not only to reduce the sentence or affirm it, but also increase it. The defendant was further advised that there is no appeal from a decision of the Sentence Review Division. The defendant acknowledged that she understood this and stated that she wished to proceed.

Rule 17 of the Rules of the Sentence Review Division of the Supreme Court of Montana provides that “the sentence imposed by the District Court is presumed correct, and the sentence will not be reduced or increased unless it is deemed clearly inadequate or excessive.” (§46-18-904(3), MCA).

*28The Division finds that the reasons advanced for modification are insufficient to hold that the sentence imposed by the District Court is inadequate or excessive.

Therefore, it is the unanimous decision of the Sentence Review Division that the sentence shall be affirmed.

Done in open Court this 2nd day of April, 2010.

DATED this 19th day of April, 2010.

Chairperson, Hon. Blair Jones, Member, Hon. Richard Simonton and Member, Hon. Ray Dayton.
Document Headings

                    Document headings vary by document type but may contain                    the following:                  
                -                       the agency or agencies that issued and signed a document                    
                -                       the number of the CFR title and the number of each part                      the document amends, proposes to amend, or is directly                      related to                    
                -                       the agency docket number / agency internal file number                    
                -                       the RIN which identifies each regulatory action listed in                      the Unified Agenda of Federal Regulatory and Deregulatory                      Actions                    

                    See the                                          Document Drafting Handbook                                        for more details.                  

###### Department of Health and Human Services

###### National Institutes of Health

      ( print page 25261)    
Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:*                         National Center for Complementary and Alternative Medicine Special Emphasis Panel; ARRA Type 3 Basic Science R21 applications.                    

*Date:*                         June 14-16, 2009.                    

*Time:*                         6 p.m. to 5 p.m.                    

*Agenda:*                         To review and evaluate grant applications.                    

*Place:*                         Residence Inn Bethesda, 7335 Wisconsin Avenue, Bethesda, MD 20814.                    

*Contact Person:*                         Peter Kozel, PhD, Scientific Review Officer, NCCAM, 6707 Democracy Boulevard, Suite 401, Bethesda, MD 20892-5475, 301-496-8004,                         *kozelp@mail.nih.gov.*

(Catalogue of Federal Domestic Assistance Program No. 93.701, ARRA Related Biomedical Research and Research Support Awards, National Institutes of Health, HHS)

Dated: May 15, 2009.

Jennifer Spaeth,

Director, Office of Federal Advisory Committee Policy.

[FR Doc. E9-12191 Filed 5-26-09; 8:45 am]

BILLING CODE 4140-01-P
```

[Congressional Bills 109th Congress]
[From the U.S. Government Publishing Office]
[S. 966 Introduced in Senate (IS)]

109th CONGRESS
  1st Session
                                 S. 966

To designate a United States courthouse located in Fresno, California, 
          as the ``Robert E. Coyle United States Courthouse''.

_______________________________________________________________________

                   IN THE SENATE OF THE UNITED STATES

                             April 28, 2005

 Mrs. Boxer (for herself and Mrs. Feinstein) introduced the following 
bill; which was read twice and referred to the Committee on Environment 
                            and Public Works

_______________________________________________________________________

                                 A BILL

 
To designate a United States courthouse located in Fresno, California, 
          as the ``Robert E. Coyle United States Courthouse''.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. DESIGNATION.

    The United States courthouse bordered by O Street, P Street, Tulare 
Street, and Capitol Street in Fresno, California, shall be known and 
designated as the ``Robert E. Coyle United States Courthouse''.

SEC. 2. REFERENCES.

    Any reference in a law, map, regulation, document, paper, or other 
record of the United States to the United States courthouse referred to 
in section 1 shall be deemed to be a reference to the ``Robert E. Coyle 
United States Courthouse''.
                                 <all>
```
UNPUBLISHED

UNITED STATES COURT OF APPEALS

FOR THE FOURTH CIRCUIT

No. 11-1778

SAKIMA IBAN SALIH EL BEY, a/k/a Francis Marion Savall, 

a/k/a Iban Salih El Bey Sakim,

Plaintiff - Appellant,

v.

LIEUTENANT DAVIS; JOE SHAW, Mayor, City of Lancaster; 

HARLEAN HOWARD, Chief of Police, Lancaster Police 

Department; NIKKI HALEY, Governor, State of SC; OFFICER 

FIREBAUGH,

Defendants - Appellees.

Appeal from the United States District Court for the District of 

South Carolina, at Rock Hill. Solomon Blatt, Jr., Senior 

District Judge. (0:11-cv-01026-SB)

Submitted: October 13, 2011 Decided: October 17, 2011

Before SHEDD, AGEE, and WYNN, Circuit Judges.

Affirmed by unpublished per curiam opinion.

Sakima Iban Salih El Bey, Appellant Pro Se.

Unpublished opinions are not binding precedent in this circuit.
2

PER CURIAM:

Sakima Iban Salih El Bey appeals the district court’s 

order dismissing his 42 U.S.C. § 1983 (2006) complaint without 

prejudice. The district court referred this case to a 

magistrate judge pursuant to 28 U.S.C.A. § 636(b)(1)(B) (West 

2006 & Supp. 2011). The magistrate judge recommended that the 

complaint be dismissed and advised El Bey that failure to timely 

file specific objections to this recommendation could waive 

appellate review of a district court order based upon the 

recommendation.

The timely filing of specific objections to a 

magistrate judge’s recommendation is necessary to preserve 

appellate review of the substance of that recommendation when 

the parties have been warned of the consequences of 

noncompliance. Wright v. Collins, 766 F.2d 841, 845-46 (4th 

Cir. 1985); see also Thomas v. Arn, 474 U.S. 140 (1985). El Bey

has waived appellate review by failing to file objections after 

receiving proper notice. Accordingly, we affirm the judgment of 

the district court.

We dispense with oral argument because the facts and 

legal contentions are adequately presented in the materials 

before the court and argument would not aid the decisional 

process.

AFFIRMED
[Federal Register Volume 74, Number 99 (Tuesday, May 26, 2009)]
[Notices]
[Page 24849]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: E9-12083]


-----------------------------------------------------------------------

DEPARTMENT OF ENERGY

Federal Energy Regulatory Commission

[Docket No. AD09-6-000]


Pipeline Siting and Stakeholder Involvement Workshop; Notice of 
Pipeline Siting and Stakeholder Involvement Workshop

May 15, 2009.
    On June 1, 2009, the Federal Energy Regulatory Commission (FERC or 
Commission) will hold a workshop, hosted by Commissioner Philip 
Moeller, on natural gas pipeline siting. The workshop will focus on the 
importance of pipeline companies working collaboratively with affected 
stakeholders throughout the environmental review and certification 
process to successfully site new pipeline infrastructure. A case study 
of a recent major pipeline project will be presented by the pipeline 
company representatives. In addition, a panel of outreach experts from 
the industry and FERC staff will provide perspectives on innovative 
approaches to stakeholder outreach and the importance of outreach 
efforts in the siting process.
    The workshop will be held at the Commission's Headquarters, 888 
First St., NE., Washington, DC 20426 in the Commission Meeting Room 
from 1 p.m. until 4:15 p.m. EST. All interested parties may attend. The 
workshop will not be transcribed, and telephone participation will not 
be available.
    Commission workshops and conferences are accessible under section 
508 of the Rehabilitation Act of 1973. For accessibility accommodations 
please send an e-mail to <a href="/cdn-cgi/l/email-protection#224341414751514b404b4e4b565b62444750410c454d54"><span class="__cf_email__" data-cfemail="bfdedcdcdaccccd6ddd6d3d6cbc6ffd9dacddc91d8d0c9">[email protected]</span></a> or call toll free 1-
866-208-3372 (voice) or 202-208-8659 (TTY), or send a FAX to 202-208-
2106 with the required accommodations.
    The agenda for the siting workshop is attached. For additional 
information concerning this event, please contact Lauren O'Donnell at 
202-502-8325 or Berne Mosley at 202-502-8625.

Kimberly D. Bose,
Secretary.

Pipeline Siting and Stakeholder Involvement Workshop Agenda

1 p.m. Welcome and Opening Remarks.
1:15 p.m. Case Study of CenterPoint Energy's Carthage to Perryville 
Pipeline Project.
Debbie Ristig, Vice President, Engineering and Compliance, CenterPoint 
Energy.
2:15 p.m. Break.
2:30 p.m. Stakeholder Outreach Panel Discussion.
Julee Stephenson, Director, Regulatory and Government Affairs, NiSource 
Gas Transmission & Storage.
Cindy Ivey, Manager, Public Outreach, Transcontinental Gas Pipeline.
Susan Waller, Vice President, Stakeholder Outreach, Spectra Energy 
Transmission.
Douglas Sipe, Outreach Coordinator, Federal Energy Regulatory 
Commission.
3:45 p.m. Questions and Closing Remarks.
4:15 p.m. Adjourn.

[FR Doc. E9-12083 Filed 5-22-09; 8:45 am]
BILLING CODE 6717-01-P


</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>
```

[Congressional Bills 111th Congress]
[From the U.S. Government Publishing Office]
[S. 2515 Introduced in Senate (IS)]

111th CONGRESS
  1st Session
                                S. 2515

  To suspend temporarily the duty on silver sodium hydrogen zirconium 
                               phosphate.

_______________________________________________________________________

                   IN THE SENATE OF THE UNITED STATES

                            October 29, 2009

  Mr. Graham introduced the following bill; which was read twice and 
                  referred to the Committee on Finance

_______________________________________________________________________

                                 A BILL

 
  To suspend temporarily the duty on silver sodium hydrogen zirconium 
                               phosphate.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. SILVER SODIUM HYDROGEN ZIRCONIUM PHOSPHATE.

    (a) In General.--Subchapter II of chapter 99 of the Harmonized 
Tariff Schedule of the United States is amended by inserting in 
numerical sequence the following new heading:

``      9902.01.00       Silver sodium       Free         No change        No change        On or before 12/ ''.
                          hydrogen                                                           31/2011.......
                          zirconium
                          phosphate (CAS
                          No. 265647-11-8)
                          (provided for in
                          subheading
                          2843.29.01)......

    (b) Effective Date.--The amendment made by subsection (a) applies 
to goods entered, or withdrawn from warehouse for consumption, on or 
after the 15th day after the date of the enactment of this Act.
                                 <all>
```
September 23, 2022              CLINICAL            

Sarfaraz Hasni, M.D. 

|

Lupus Clinical Trials Unit

|

## Description

Women with systemic lupus erythematosus (SLE) face fertility and pregnancy challenges. Commonly used chemotherapeutic agents for SLE, such as cyclophosphamide (CYC), can cause gonado-toxicity, premature ovarian failure, and abnormal levels of reproductive hormones in premenopausal women with SLE. By analyzing data from existing literature, this study provides evidence that gonadotropin-releasing hormone (GnRH) agonists have protective effects on ovarian function in lupus patients receiving CYC treatment.

## What is exciting about this article?

For women with SLE, the likelihood of experiencing a flare-up is higher during pregnancy, which can lead to adverse pregnancy outcomes. CYC, used to treat SLE, can cause premature ovarian failure and decreased levels of reproductive hormones. Embryo and oocyte cryopreservation is a costly and time-consuming procedure and often results in a high rate of fetal and maternal complications in women with lupus. According to this meta-analysis, GnRH agonists are effective in protecting the ovaries and increasing the odds of pregnancy in SLE patients who receive CYC treatment, in a noninvasive and relatively safe manner. In addition to determining the effectiveness and side effects of GnRH agonists in a large population of patients with SLE and other autoimmune conditions, this study indicates that more clinical trials with GnRH agonists might be needed.

## How does this fit into the larger NIAMS portfolio?

This report suggests that GnRH agonists are effective in protecting the ovaries and increasing the possibility of pregnancy among premenopausal SLE females who are treated with CYC.

## Grant support

AR041232

Research Areas:
AutoimmunityClinical ResearchImmunology

Reference:

###             Use of gonadotropin-releasing hormone agonists for ovarian preservation in patients receiving cyclophosphamide for systemic lupus erythematosus: A meta-analysis.        

31(14).

Research reported in this publication was supported by the Intramural Research Program of the NIHʼs National Institute of Arthritis and Musculoskeletal and Skin Diseases.

Previous

See All Advances

Next

## Recent Advances

Selected recent highlights of NIAMS intramural research:

October 3, 2023

The Transcription Factor STAT4 Controls the Fate of Cytotoxic Innate Lymphocytes

September 26, 2023

Genetic Variants of PLCG2 Cause Immune Dysregulation Through Either Increased or Decreased Function

September 26, 2023

The Microbiomes of People with Recombination-Activating Gene (RAG) Deficiency Have Distinct Features, Including Antimicrobial Resistance Signatures 

September 23, 2023

Neutrophil Extracellular Traps (NETs) Trigger Pathogenic Inflammation and Bone Loss in Periodontitis

September 22, 2023

Possible Mechanism of a Rare Bone Overgrowth Disease Identified

Back to Top
#### UNITED STATES of America, Plaintiff—Appellee, v. Christopher WALKER, Defendant—Appellant.

No. 09-6040.

United States Court of Appeals, Fourth Circuit.

Submitted: April 23, 2009.

Decided: May 5, 2009.

*164Christopher Walker, Appellant Pro Se. Sara Elizabeth Chase, Joan Elizabeth Evans, Norval George Metcalf, Assistant United States Attorneys, Richmond, Virginia, for Appellee.

Before MICHAEL, GREGORY, and DUNCAN, Circuit Judges.

Affirmed by unpublished PER CURIAM opinion.

Unpublished opinions are not binding precedent in this circuit.

PER CURIAM:

Christopher Walker appeals the district court’s order denying his motion for reduction of sentence pursuant to 18 U.S.C. § 3582(c) (2006). We have reviewed the record and find no reversible error. Accordingly, we affirm for the reasons stated by the district court. *United States v. Walker,*No. 3:96-cr-00123-REP-2 (E.D.Va. Dec. 8, 2008); *see also United States v. Dunphy,*551 F.3d 247 (4th Cir.2009). We further deny Walker’s motion for appointment of counsel. We dispense with oral argument because the facts and legal contentions are adequately presented in the materials before the court and argument would not aid the decisional process.

*AFFIRMED.*
Exhibit 32.1
 CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER
PURSUANT TO 18 U.S.C. SECTION 1350
  (1)
    
    The Report fully complies with the requirements of section 13(a) or 15(d) of the
Securities Exchange Act of 1934; and
 (2)
    
    The information contained in the Report fairly presents, in all material respects, the
financial condition and results of operations of Full House Resorts, Inc.
 Dated: March 23, 2010
    By:
    /s/ ANDRE M. HILLIOUAndre M. HilliouChief Executive Officer




---



##### 



CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER
PURSUANT TO 18 U.S.C. SECTION 1350
  (1)
    
    The Report fully complies with the requirements of section 13(a) or 15(d) of the
Securities Exchange Act of 1934; and
 (2)
    
    The information contained in the Report fairly presents, in all material respects, the
financial condition and results of operations of Full House Resorts, Inc.
 Dated: March 23, 2010
    By:
    /s/ MARK MILLERMark MillerChief Financial Officer and Chief Operating Officer
<TABLE> <S> <C>

<ARTICLE>      5
<MULTIPLIER>   1,000
<PERIOD-TYPE>                   Year
<FISCAL-YEAR-END>                    DEC-31-1996
<PERIOD-START>                       JAN-01-1996
<PERIOD-END>                         DEC-31-1996
<CASH>                                        22
<SECURITIES>                                   0
<RECEIVABLES>                              2,160
<ALLOWANCES>                                   0
<INVENTORY>                                    0
<CURRENT-ASSETS>                           2,182
<PP&E>                                    44,333
<DEPRECIATION>                            40,346
<TOTAL-ASSETS>                             6,169
<CURRENT-LIABILITIES>                        600
<BONDS>                                    5,400
<PREFERRED-MANDATORY>                          0
<PREFERRED>                                    0
<COMMON>                                       0
<OTHER-SE>                                   169
<TOTAL-LIABILITY-AND-EQUITY>               6,169
<SALES>                                    4,807
<TOTAL-REVENUES>                           4,991
<CGS>                                          0
<TOTAL-COSTS>                                813
<OTHER-EXPENSES>                           1,605
<LOSS-PROVISION>                               0
<INTEREST-EXPENSE>                           810
<INCOME-PRETAX>                            1,763
<INCOME-TAX>                                   0
<INCOME-CONTINUING>                            0
<DISCONTINUED>                                 0
<EXTRAORDINARY>                                0
<CHANGES>                                      0
<NET-INCOME>                               1,763
<EPS-PRIMARY>                                .69
<EPS-DILUTED>                                .69


</TABLE>
Exhibit 32.1

CERTIFICATION OF CHIEF EXECUTIVE OFFICER AND CHIEF FINANCIAL OFFICER

PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

I, Richard W. Koe, certify to the best of my knowledge,
pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that the Quarterly Report of TigerLogic Corporation on Form 10-Q for the quarterly period ended September 30, 2009 fully
complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and that information contained in such Form 10-Q fairly presents in all material respects the financial condition and results of
operations of TigerLogic Corporation for the periods presented therein.

Date: November 12, 2009



By:

/s/    Richard W. KoeName:

Richard W. KoeTitle:

Interim President and Chief Executive Officer


I, Thomas Lim, certify to the best of my knowledge, pursuant to 18 U.S.C.
Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that the Quarterly Report of TigerLogic Corporation on Form 10-Q for the quarterly period ended September 30, 2009 fully complies with the
requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and that information contained in such Form 10-Q fairly presents in all material respects the financial condition and results of operations of
TigerLogic Corporation for the periods presented therein.

Date: November 12, 2009



By:

/s/    Thomas LimName:

Thomas LimTitle:

Chief Financial Officer
{"status":true,"count":1,"text":"\u003Cp class=\u0022messages messages--status\u0022\u003EAdded to cart\u003C\/p\u003E","id":"ajax-addtocart-message-7636","block":"\u003Cdiv class=\u0022basic_cart-grid basic-cart-block\u0022\u003E\n  \n\n          \u003Cdiv class=\u0022basic_cart-cart-contents row\u0022\u003E\n        \u003Cdiv class=\u0022basic_cart-cart-node-title cell\u0022\u003E\u003Ca href=\u0022\/publication-products\/age-related-hearing-loss\u0022\u003EAge-Related Hearing Loss\u003C\/a\u003E \u003C\/div\u003E\n              \n        \u003Cdiv class=\u0022basic_cart-cart-unit-price cell\u0022\u003E\n        \u003Cstrong\u003E\u003C\/strong\u003E    \n        \u003C\/div\u003E\n    \u003C\/div\u003E\n      \n  \u003Cdiv class=\u0022basic_cart-cart-total-price-contents row\u0022\u003E\n        \u003Cdiv class=\u0022basic_cart-total-price cell\u0022\u003E\n            Total Price: \u003Cstrong\u003E 0,00 USD \u003C\/strong\u003E\n        \u003C\/div\u003E\n      \u003C\/div\u003E \n\n\n         \n\n\n       \u003Cdiv class=\u0022basic_cart-cart-checkout-button basic_cart-cart-checkout-button-block row\u0022\u003E\n        \u003Ca href=\u0027\/cart\u0027 class=\u0027button\u0027\u003EView cart \u003C\/a\u003E\n      \u003C\/div\u003E\n\n\n  \u003C\/div\u003E"}